TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Newly diagnosed histologically confirmed stage I-III, ER, PR and HER2 negative invasive breast cancer as defined by the ASCO CAP guidelines for whom systemic chemotherapy would be indicated based on physician judgment following standard NCCN practice guidelines.~2. Willing and able to provide written informed consent for voluntary participation in the trial.~3. Willing to undergo a baseline tumor core needle biopsy and blood draws for correlative science studies.~4. Eighteen years of age or older on the day of signing informed consent.~5. Female subjects must either be of non-reproductive potential or must have a negative urine or serum pregnancy test upon study entry.~6. Patients should have adequate organ function to tolerate chemotherapy, as defined by:~   * peripheral granulocyte count of \> 1,500/mm3~  * platelet count \> 100,000/mm3~  * hemoglobin \>9 g/dL~  * total bilirubin \< 1.5 x upper limit of normal (ULN)~  * aspartate aminotransferase (AST) and alanine aminotransferase (ALT) each \< 1.5 x ULN~  * serum creatinine \< 1.5 x ULN or serum creatinine clearance \< 50mL/min~  * INR/PT/PTT each \< 1.5 x ULN~  * TSH within normal limits~Exclusion Criteria:~1. Patients who underwent partial excisional biopsy or lumpectomy, segmental mastectomy or modified radical mastectomy or sentinel node.~2. Patients for whom anthracycline, paclitaxel or antibody therapies are contraindicated.~3. Patients with active autoimmune disease or documented autoimmune disease within 2 years. Patients with hypothyroidism that is clinically stable and have normal TSH levels with hormone replacement, or patients with vitiligo or psoriasis not requiring treatment remain eligible for the study.~4. Active or prior documented inflammatory bowel disease (Crohn's disease, ulcerative colitis).~5. Patients with known active hepatitis B or C or HIV infection or with history of tuberculosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MEDI4736 (Type: EXPERIMENTAL): The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of 3 Months of Selective Serotonin Reuptake Inhibitor (SSRI)-Treatment on Metabolism and Hypothalamic-pituitary-adrenal (HPA)-Axis in Young Men Born With Low Birth Weight

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy men 20-35 years old.~2. birth weight \<2500g.~3. Born at gestational week 38- 40 (42).~Exclusion Criteria:~1. Diabetes, insulin-resistance or precursors in first degree relatives or maternal gestational diabetes.~2. Small parents(mother \<160cm and/or father \<170cm).~3. History of abuse of alcohol, medicine og drugs in the mother during pregnancy.~4. Liver of renal failure : s-ALAT \> 2.5 normal upper limit (\>175μM) or s-creatinine \>125 μmol/l.~5. Co-morbidity that after at medical examination is considered to be a problem.~6. BMI\>25.5~7. Smoking that is considered to be an issue as regards completing the study.~8. Treatment with a MAO-inhibitor.~9. Born before gestational week 38.~10. Participation in larger X-ray examinations such CT-scans during the last 12 months.~11. Participation in medical experiments or treatments involving intravenous administration of radioactive substances during the last~12. Ongoing medical treatment that will be considered a issue for completing the study.~13. Allergy towards the substance Escitalopram.~14. Metal parts in the body that contra-indicates MRI.~15. Ongoing medical treatment thrombocyte inhibiting substances such as NSAIDS.~16. Previous gastrointestinal bleeding or gastro-duodenal ulcers.~17. Depression during examination or treatment~16/05-2011: Criterias updated - added 17 and adjusted 6. from BMI \>25 to BMI \>25.5

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- escitalopram (Type: ACTIVE_COMPARATOR): A pill containing Escitalopram
- placebo (Type: PLACEBO_COMPARATOR): a placebo pill

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age 55 to 85 years;~2. should have a mild-to-moderate AD diagnosis (MMSE 10-26 inclusive);~3. should have evidence of elevated cortical amyloid by PET using florbetapir F18 (Amyvid) \[i.e. a positive scan\], assessed qualitatively according to the Amyvid product label.~4. if on anti-dementia treatment should be on stable treatment for at least 2 months (i.e. cholinesterase inhibitor and/or Memantine or Axona);~5. stable on all other medications for at least 30 days prior to screen;~6. should be fluent in English;~7. should be physically able to participate by medical history, clinical exam and tests;~8. should have a study partner to accompany them to scheduled visits.~Exclusion Criteria:~1. clinically relevant arrhythmias;~2. a resting pulse less than 50;~3. active cancer other than non-melanoma skin cancers;~4. use of another investigatory drug within 2 months of screening;~5. significant stroke or head trauma by history or MRI;~6. contraindication for having a MRI;~7. diagnostic and Statistical Manual of Mental Disorders-IV criteria for a current major psychiatric disorder;~8. sensitivity to yeast or yeast products;~9. impaired kidney function as measured by a Glomerular Filtration Rate less than 60 milliliters/min;~10. preexisting fluid retention, pulmonary infiltrates, or congestive heart failure;~11. history of moderate-to-severe lung disease;~12. history of moderate-to-severe liver disease;~13. pregnant women, or any women who feel they are likely to become pregnant during the study;~14. prisoners.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Sagramostim (Leukine) (Type: EXPERIMENTAL): 5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
- Control Group (Type: PLACEBO_COMPARATOR): Saline -- placebo comparator. Given as a subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Canadian Pegvisomant Compassionate Study In Acromegalic Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have participated and completed the previous Pegvisomant studies or have shown to be unresponsive to other conventional therapies~Exclusion Criteria:~* ALT/AST\>3 times the ULN or have hepatic disease~* have severe visual field loss, cranial nerve palsies or intracranial HTN that requires surgery to decompress the tumor~* unwilling to self-administer the medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transesophageal Magnetic Resonance Imaging (MRI) in Conjunction With Lipid Lowering Measures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years~* Required to have documented atherosclerosis in at least 1 vascular territory defined as: at least moderate (\>3.9mm) aortic atherosclerosis seen on transesophageal echocardiography; or moderate coronary artery disease (\>50% lesion) in at least 1 coronary artery seen at cardiac catheterization; or \>50% carotid lesion seen on ultrasound; or clinically documented peripheral vascular disease.~Exclusion Criteria:~* Patients could be on any statin therapy at entry, but not on a dose equivalent to or greater than 80mg of simvastatin.~* Patients with pacemakers, automated implanted cardioverter defibrillators (AICD), aneurysm clips, abnormal nasopharyngeal anatomy, active peptic ulcer disease, severe dysphagia, elevated baseline liver transaminases and serum creatinine (greater than 2 times the normal), decompensated congestive heart failure or inability to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Based Acoustic Radiation Force Impulse Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or younger~* Scheduled to have a needle biopsy of the liver at~  1. C.S. Mott Children's Hospital or~ 2. Dept. of Radiology at the Univ. of Michigan Hospital~* Scheduled to have an abdominal ultrasound to evaluate your liver (with no known liver disease)~Exclusion Criteria:~* None to list

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Ultrasound-based Acoustic Radiation Force Imaging (Type: EXPERIMENTAL): The liver was scanned using ultrasound and ultrasound-based acoustic radiation force impulse imaging technique (ARFI).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hemostatic Effects of Ulinastatin and Tranexamic Acid in Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Atrial or ventricular septum defect patients requiring cardiac surgery with CPB~* Rheumatic or recessive valvular patients requiring valvular repair or replacement with CPB~* Coronary artery disease patients requiring coronary revascularization surgery with CPB~Exclusion Criteria:~* Non-primary cardiac surgery~* Definite liver or renal dysfunction~* Disorder in coagulation function~* Allergy~* Pregnancy or lactation~* Disabled in spirit or law~* Fatal conditions such as tumour

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Ulinastatin (Type: EXPERIMENTAL): 1,000,000 units of ulinastatin in 50ml solution before skin incision; 50ml saline solution after neutralization
- Tranexamic Acid (Type: EXPERIMENTAL): 15mg/kg tranexamic acid in 50ml solution before skin incision; 15mg/kg tranexamic acid in 50ml solution after neutralization
- Placebo (Type: PLACEBO_COMPARATOR): 50ml saline solution before skin incision; 50ml saline solution after neutralization

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Efficacy Between 100% Platelet-rich Plasma and 100% Serum Eye Drops in Dry Eye Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 to less than 75 years.~* Have OSDI scores ≥ 23 or Oxford staining grade ≥ 2.~* Do not have following conditions:~Uncontrolled systemic diseases, active infection, advanced cancer. Pregnant and nursing women. • Have not recently used the following medications/interventions/surgery: Anticoagulants or anti-platelets. Topical undiluted blood products within 3 months. Punctal plug or contact lenses. Ocular surgery within 6 months.~* Do not have active ocular infection/inflammation, abnormal eyelid function or severe meibomian gland dysfunction (MGD stage 4).~* Have no contraindication for blood donations:~Positive human immunodeficiency virus, hepatitis B or C, or syphilis. Anemia (Hb \< 11 g/dL) or platelet concentration \< 150,000/ml.~* Being able to stop current dry eye treatment for 48 hours before staring trial intervention~* Willing to comply with the 4-week study protocol and provide informed consent.~Exclusion Criteria:~• None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 100% APRP (Type: EXPERIMENTAL): Patients will be instructed to apply every 2 hours (8 times/day). The currently used bottle will be required to store at 4 C for 24 hours, and the remaining bottles at -20 C in a freezer until day of use.
- 100% AS (Type: ACTIVE_COMPARATOR): Patients will be instructed to apply every 2 hours (8 times/day). The currently used bottle will be required to store at 4 C for 24 hours, and the remaining bottles at -20 C in a freezer until day of use.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Closed-loop Glucose Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* The subject is aged 18 years or over~* Diagnosis of type 2 diabetes using standard diagnostic practice (37)~* The subject is planned for an elective abdominal, thoracic or cardiovascular surgery at the University Hospital Bern expected to last ≥2 hours~* The subject requires treatment with subcutaneous insulin as part of the perioperative glucose management~* The subject is literate in German~* The subject is willing to wear study devices 24/7~Exclusion Criteria:~* Physical or psychological condition likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator~* Known or suspected allergy to insulin~* Type 1 diabetes~* Pregnancy, planned pregnancy, or breast feeding~* Medically documented allergy towards the adhesive (glue) of plasters or unable tolerate tape adhesive in the area of sensor placement~* Lack of safe contraception for female participants of childbearing potential for the entire study duration (medically reliable method of contraception are considered oral, injectable, or implantable contraceptives, intrauterine contraceptive devices, or any other methods judged as sufficiently reliable by the investigator in individual cases).~* Serious skin diseases located at places of the body, which potentially are possible to be used for localisation of the glucose sensor~* Illicit drug abuse or prescription drug abuse~* Incapacity to give informed consent~* Droplet/airborne isolation precautions~* Participation in another clinical trial that interferes with the interpretation of the study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Closed-loop insulin therapy (Type: EXPERIMENTAL): None
- Standard insulin therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females must be practicing specific forms of birth control on study treatment, or be post-menopausal for more than 2 years or surgically sterile~* Male or female between 18 and 70 years, inclusive, at time of Screening.~* Chronic HCV-infection prior to study enrollment.~* Screening laboratory result indicating HCV genotype 1-infection.~* Compensated cirrhosis defined as a Child-Pugh Score of less than or equal to 6 at Screening~* Subject has plasma HCV RNA level greater than 10,000 IU/mL at Screening.~Exclusion Criteria:~* Significant liver disease with any cause other than HCV as the primary cause~* Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency virus antibody (HIV Ab) at screening.~* Prior therapy with direct acting antiviral agents for the treatment of HCV, including telaprevir and boceprevir.~* Any current or past clinical evidence of Child-Pugh B or C Classification or clinical history of liver decompensation including ascites (noted on physical exam), variceal bleeding or hepatic encephalopathy.~* A positive screening ultrasound for hepatocellular carcinoma (HCC) confirmed with a subsequent CT Scan or MRI during the screening period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks (Type: EXPERIMENTAL): ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if \<75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks
- ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks (Type: EXPERIMENTAL): ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if \<75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* The participant has a diagnosis of migraine as defined by International Classification of Headache Disorders Third Edition (ICHD-3) guidelines confirmed at the Screening Visit.~* The participant has a history of migraine onset at least 12 months prior to the Screening Visit.~* The participant has a migraine onset at ≤50 years of age.~* The participant has documented evidence of treatment failure in the past 10 years of at least 2 to 4 (maximum) different migraine preventive medications.~Key Exclusion Criteria:~* The participant has been previously dosed with an anti-pituitary adenylate cyclase-activating polypeptide (anti-PACAP) ligand-targeting antibody.~* The participant has confounding and clinically significant pain syndromes.~* The participant has a diagnosis of acute or active temporomandibular disorder.~* The participant has a history or diagnosis of confounding headaches.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lu AG09222 High Dose (Type: EXPERIMENTAL): Participants will receive a single high dose of Lu AG09222 by intravenous (IV) infusion.
- Lu AG09222 Low Dose (Type: EXPERIMENTAL): Participants will receive a single low dose of Lu AG09222 by IV infusion.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive a single dose of placebo matching to Lu AG09222 by IV infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete